"There is more new independent Brilacidin research almost every week. "
Sadly the other re word, revenue, is nowhere to be seen. If only Leo could pay himself (I almost said "the bills") with research.
This antibiotic/MRSA issue never fails to amaze me. These things have all been propounded here:
1. It's too expensive for IPIX to pursue.
2. There's not enough of a market for it.
3. No BPs appreciate brilacidin in spite of the trial results.
4. BP and the FDA have conspired against IPIX to assure that B won't be approved.
None of that stops you and others from singing B's antibiotic praises. Even the failure to take a single baby step forward with B-ABSSSI since 2016 doesn't seem to deter you. How do you address the 4 stumbling blocks, real and/or imagined, in order to find a way forward?
News 
Market Data 
Discover 
AI
